To evaluate the clinical pregnancy outcomes of fresh embryo transfer at the cleavage stage utilizing gonadotropin-releasing hormone agonist (GnRH-a) and the antagonist protocols in young patients with poor prognosis. A retrospective cohort study was carried out on patients who underwent in vitro fertilization-embryo transfer (IVF-ET) between January 2016 and July 2024. Women under 35 years old with anti-Müllerian hormone (AMH) levels 0.05). Multivariate logistic regression analysis revealed that the clinical pregnancy rate in the GnRH-a group (OR = 1.25,95%CI:1.02, 1.52) was 1.25 times higher than that in the antagonist group ( P = 0.0297), and the live birth rate(OR = 1.38,95%CI:1.12, 1.71) was 1.38 times higher ( P = 0.0025). Additionally, compared to the antagonist group (transfer cancellation rate: 45.71%; total embryo freezing: 31.58%), the GnRH-a group exhibited reduced rates of fresh cycle transfer cancellation (34.67%; P 0.05). In young patients with poor prognosis, the GnRH-a protocol for controlled ovarian stimulation in fresh embryo transfer cycles produces higher clinical pregnancy and live birth rates, as well as a lower fresh transfer cancellation rate, as compared to the antagonist protocol.
Jia et al. (Fri,) studied this question.